ClinicalTrials.Veeva

Menu

Impact of Intestinal Virome on Pediatric Inflammatory Bowel Disease (IVOIRE)

Civil Hospices of Lyon logo

Civil Hospices of Lyon

Status

Completed

Conditions

Inflammatory Bowel Diseases

Treatments

Other: Collection of stool and blood samples

Study type

Observational

Funder types

Other

Identifiers

NCT03967236
69HCL18_0794

Details and patient eligibility

About

Over the last few years, dysbiosis has emerged as a possible trigger of gut inflammation in inflammatory bowel disease (IBD) and a promising therapeutic target. The complex diversity of microbiota was initially highlighted by the powerful new tools in genetics, including next-generation sequencing (NGS). NGS permitted to decipher the composition of bacterial intestinal communities, but also that of the gut virome. Since then, the evidence of a dynamic instability of the enteric virome in IBD has grown considerably. IBD patients present an expansion of bacteriophages (Caudovirales) associated with decreased bacterial diversity. Moreover, gut virome richness seems to differ between Crohn's disease (CD) and ulcerative colitis (UC) patients. These insights open the gate of new diagnostic, predictive, and therapeutic approaches. However, little is known about pediatric IBD gut virome in terms of variability and evolution under the influence of different treatments (exclusive enteral nutrition, immunosuppressive therapy and biologics). The aim of this study is to evaluate the gut family viral diversity and relative abundance of eukaryotes and prokaryotes in paediatric IBD patients

Enrollment

20 patients

Sex

All

Ages

6 to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age: 6-17 years

  • Follow-up in pediatric gastroenterology for inflammatory bowel disease :

    • Crohn's disease
    • Hemorrhagic rectocolitis
  • Introduction of anti-TNFa treatment in the Pediatric Gastroenterology Day Hospital of the "Hôpital Femme Mère Enfant" service in Lyon

  • Collection of the non-opposition of at least one of the holders of the parental authority present and the child in the medical file

Exclusion criteria

  • Refusal to participate in the study
  • Antibiotherapy in the 4 weeks preceding the sampling
  • Patient with ileostomy or colostomy.
  • Patient who has undergone extensive bowel resection.
  • History of intestinal surgery (except appendectomy)
  • Patient subject to a legal protection measure

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems